<DOC>
	<DOCNO>NCT00003065</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness topotecan paclitaxel treat patient recurrent metastatic cancer cervix .</brief_summary>
	<brief_title>Topotecan Paclitaxel Treating Patients With Recurrent Metastatic Cancer Cervix</brief_title>
	<detailed_description>OBJECTIVES : - Determine response , time progression , disease free survival , overall survival patient recurrent and/or metastatic cancer cervix treat combination topotecan paclitaxel . - Determine feasibility toxicity regimen patient . OUTLINE : Patients receive paclitaxel IV 3 hour day 1 topotecan IV 30 minute day 1-5 . Filgrastim ( G-CSF ) administer day 6-14 . Treatment repeat every 21 day minimum 2 course absence disease progression unacceptable toxicity . Patients follow every 3 week . PROJECTED ACCRUAL : A total 25 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent , persistent metastatic cervical carcinoma ( squamous adenocarcinoma ) , potentially curative standard treatment Measurable disease evaluable disease PATIENT CHARACTERISTICS : Age : 18 physiological 60 Performance status : ECOG 02 Life expectancy : Greater 2 month Hematopoietic : WBC great 3000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 time normal SGOT/SGPT le 1.5 time normal Renal : BUN le 1.5 time normal Creatinine le 1.5 time normal Creatinine clearance great 50 mL/min Other : Ineligible high priority national institutional study Not pregnant nursing HIV negative No prior malignancy except nonmelanoma skin cancer No serious medical psychiatric illness prevent treatment informed consent PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Greater 4 week since prior chemotherapy No great 2 prior chemotherapy regimens No prior taxane camptothecin Endocrine therapy : No concurrent hormonal therapy except require nondisease related condition ( e.g. , insulin diabetes ) Radiotherapy : Greater 4 week since prior radiation therapy No concurrent radiation therapy Surgery : Greater 4 week since prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
</DOC>